Shop by Category
NAD+ 1,000mg
Summary Description: Nicotinamide adenine dinucleotide (NAD⁺) is a ubiquitous pyridine nucleotide coenzyme present in all living cells. It serves critical roles in cellular redox reactions for energy metabolism and acts as an essential substrate for key signaling enzymes regulating DNA repair, gene expression, and cell signaling. Cellular NAD⁺ levels influence metabolic health, stress response, and tissue regeneration1,3.
Products will arrive in a lyophilized (powder) form for maximum stability
NAD+ 500mg
Summary Description: Nicotinamide adenine dinucleotide (NAD⁺) is a ubiquitous pyridine nucleotide coenzyme present in all living cells. It serves critical roles in cellular redox reactions for energy metabolism and acts as an essential substrate for key signaling enzymes regulating DNA repair, gene expression, and cell signaling. Cellular NAD⁺ levels influence metabolic health, stress response, and tissue regeneration1,3.
Products will arrive in a lyophilized (powder) form for maximum stability
PT-141 10mg
Summary Description: PT-141 is a synthetic cyclic heptapeptide derivative of alpha-melanocyte stimulating hormone (α-MSH), designed to act as a potent and selective melanocortin receptor agonist, particularly at MC3 and MC4. It is primarily researched for its unique ability to induce sexual arousal and enhance sexual function in both men and women without acting via direct hormonal or vascular mechanisms. PT-141 is supplied strictly for laboratory research use1,2,4.
Products will arrive in a lyophilized (powder) form for maximum stability
Retatrutide 10mg
Summary Description: Retatrutide is a next-generation investigational medication initially developed for the treatment of obesity and type 2 diabetes, with emerging evidence highlighting its potential multi-system benefits. Retatrutide is a synthetic peptide based on a glucose-dependent insulinotropic polypeptide (GIP) backbone, but uniquely, it functions as a triple agonist. This means it simultaneously activates the receptors for GIP, glucagon-like peptide-1 (GLP-1), and glucagon. Through this triple-receptor agonism, retatrutide not only lowers blood glucose levels and enhances insulin sensitivity but also suppresses appetite, increases energy expenditure, and reduces body weight. Early clinical studies suggest that retatrutide may improve cardiometabolic profiles by reducing blood pressure and improving lipid levels, further underscoring its promise for addressing both metabolic and cardiovascular risk factors in individuals with obesity and diabetes.
Products will arrive in a lyophilized (powder) form for maximum stability
Retatrutide 15mg
Summary Description: Retatrutide is a next-generation investigational medication initially developed for the treatment of obesity and type 2 diabetes, with emerging evidence highlighting its potential multi-system benefits. Retatrutide is a synthetic peptide based on a glucose-dependent insulinotropic polypeptide (GIP) backbone, but uniquely, it functions as a triple agonist. This means it simultaneously activates the receptors for GIP, glucagon-like peptide-1 (GLP-1), and glucagon. Through this triple-receptor agonism, retatrutide not only lowers blood glucose levels and enhances insulin sensitivity but also suppresses appetite, increases energy expenditure, and reduces body weight. Early clinical studies suggest that retatrutide may improve cardiometabolic profiles by reducing blood pressure and improving lipid levels, further underscoring its promise for addressing both metabolic and cardiovascular risk factors in individuals with obesity and diabetes.
Products will arrive in a lyophilized (powder) form for maximum stability
Semaglutide 10mg
Summary Description: Semaglutide is a synthetic, long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) used primarily for the treatment of type 2 diabetes and, at higher doses, for chronic weight management in adults with overweight or obesity. It mimics endogenous GLP-1, enhancing glucose-dependent insulin secretion, decreasing glucagon secretion, and significantly reducing appetite and energy intake, which leads to clinically meaningful weight loss. Structurally, semaglutide is a modified peptide analog of human GLP-1, designed to resist enzymatic degradation and prolong its biological half-life, allowing for once-weekly subcutaneous injection.
Products will arrive in a lyophilized (powder) form for maximum stability
Semaglutide 5mg
Summary Description: Semaglutide is a synthetic, long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) used primarily for the treatment of type 2 diabetes and, at higher doses, for chronic weight management in adults with overweight or obesity. It mimics endogenous GLP-1, enhancing glucose-dependent insulin secretion, decreasing glucagon secretion, and significantly reducing appetite and energy intake, which leads to clinically meaningful weight loss. Structurally, semaglutide is a modified peptide analog of human GLP-1, designed to resist enzymatic degradation and prolong its biological half-life, allowing for once-weekly subcutaneous injection.
Products will arrive in a lyophilized (powder) form for maximum stability
SLU-PP-332 250mcg x 100ct
Summary Description: SLU-PP-332 is a synthetic pan estrogen receptor-related receptor (ERRα/β/γ) agonist optimized for high potency toward ERRα and engineered with favorable pharmacokinetics for in vivo research. Functioning as a potent “exercise mimetic,” this small-molecule compound enhances mitochondrial function, fatty acid oxidation, and oxidative muscle fiber composition, thereby improving exercise endurance, cardiac metabolic efficiency, and systemic energy expenditure without increasing food intake1-4.
SS-31 50mg
Summary Description: SS-31 (Elamipretide) is a synthetic mitochondria-targeting tetrapeptide that binds selectively to cardiolipin in the inner mitochondrial membrane. It acts as a mitochondrial protective agent, stabilizing mitochondrial structure, enhancing oxidative phosphorylation, reducing production of reactive oxygen species (ROS), and mitigating cellular damage in diverse models of mitochondrial dysfunction. Owing to its unique structure and mode of action, SS-31 demonstrates potential therapeutic value across cardiovascular diseases, neurodegenerative disorders, kidney injury, and myopathies associated with mitochondrial dysfunction1-6.
Products will arrive in a lyophilized (powder) form for maximum stability
TB-500 10mg
Summary Description: TB-500 is a synthetic heptapeptide analog of the actin-binding motif of thymosin β4 (Tβ4), composed of the acetylated sequence Ac-LKKTETQ. This fragment conserves the principal bioactive domain associated with Tβ4’s regenerative activity. TB-500 has been shown to promote cell migration, angiogenesis, cytoskeletal reorganization, and anti-inflammatory signaling in preclinical models1,2. Due to its shorter sequence, TB-500 offers enhanced metabolic stability and amenability to synthetic optimization compared to the parent protein. While TB-500 is banned in competitive sports, it continues to be studied for its potential in promoting angiogenesis, tissue repair, and modulation of actin-binding proteins.
Products will arrive in a lyophilized (powder) form for maximum stability
Tesamorelin 10mg
Summary Description: Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH), developed for the reduction of excess abdominal fat in HIV-associated lipodystrophy. It stimulates endogenous growth hormone (GH) secretion, thereby increasing insulin-like growth factor-1 (IGF-1) levels and promoting lipolysis. Tesamorelin selectively reduces visceral adipose tissue (VAT) without significant effects on subcutaneous fat and improves body image parameters. Its stability-enhancing N-terminal modification allows for effective subcutaneous administration, and it is FDA-approved for HIV-related lipodystrophy.
Products will arrive in a lyophilized (powder) form for maximum stability
Tesamorelin 20mg
Summary Description: Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH), developed for the reduction of excess abdominal fat in HIV-associated lipodystrophy. It stimulates endogenous growth hormone (GH) secretion, thereby increasing insulin-like growth factor-1 (IGF-1) levels and promoting lipolysis. Tesamorelin selectively reduces visceral adipose tissue (VAT) without significant effects on subcutaneous fat and improves body image parameters. Its stability-enhancing N-terminal modification allows for effective subcutaneous administration, and it is FDA-approved for HIV-related lipodystrophy.